MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Iovance Biotherapeutics Inc

Fechado

SetorSaúde

3.25 -8.19

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.19

Máximo

3.52

Indicadores-chave

By Trading Economics

Rendimento

5M

-79M

Vendas

15M

74M

EPS

-0.26

Margem de lucro

-106.602

Funcionários

838

EBITDA

14M

-75M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+460.17% upside

Dividendos

By Dow Jones

Próximos Ganhos

8 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-524M

1.2B

Abertura anterior

11.44

Fecho anterior

3.25

Sentimento de Notícias

By Acuity

50%

50%

180 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Iovance Biotherapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de abr. de 2025, 23:55 UTC

Ações em Alta

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 de abr. de 2025, 22:50 UTC

Grandes Movimentos do Mercado

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 de abr. de 2025, 21:08 UTC

Ganhos

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 de abr. de 2025, 21:00 UTC

Ganhos

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 de abr. de 2025, 23:56 UTC

Conversa de Mercado

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 de abr. de 2025, 23:44 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de abr. de 2025, 23:44 UTC

Conversa de Mercado

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 de abr. de 2025, 23:44 UTC

Principais Notícias

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 de abr. de 2025, 23:32 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 23:32 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 de abr. de 2025, 23:32 UTC

Conversa de Mercado

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 de abr. de 2025, 23:12 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de abr. de 2025, 23:12 UTC

Conversa de Mercado

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 de abr. de 2025, 23:10 UTC

Conversa de Mercado

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 de abr. de 2025, 23:09 UTC

Conversa de Mercado

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 de abr. de 2025, 23:09 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 22:57 UTC

Conversa de Mercado

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 de abr. de 2025, 22:56 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 22:56 UTC

Conversa de Mercado

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 de abr. de 2025, 22:43 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 de abr. de 2025, 22:12 UTC

Conversa de Mercado

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 de abr. de 2025, 21:48 UTC

Principais Notícias

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 de abr. de 2025, 21:41 UTC

Conversa de Mercado

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 de abr. de 2025, 21:17 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 21:17 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 de abr. de 2025, 21:17 UTC

Conversa de Mercado

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 de abr. de 2025, 21:04 UTC

Principais Notícias

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 de abr. de 2025, 21:03 UTC

Conversa de Mercado

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 de abr. de 2025, 20:53 UTC

Ganhos

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 de abr. de 2025, 20:52 UTC

Ganhos

Kaiser Aluminum Changes Inventory Acctg Methodology

Comparação entre Pares

Variação de preço

Iovance Biotherapeutics Inc Previsão

Preço-alvo

By TipRanks

460.17% parte superior

Previsão para 12 meses

Média 19.83 USD  460.17%

Máximo 32 USD

Mínimo 6 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Iovance Biotherapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

12

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

3.2 / 3.42Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

No Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

180 / 386 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.